Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Melanoma × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 68 Hodgkin Disease 49 Lymphoma 19 Sarcoma 13 Neoplasm Metastasis 10 Leiomyosarcoma 8 Skin Neoplasms 6 Neoplasms 6 Uveal Melanoma 5 Sarcoma, Synovial 3 Recurrence 3 Solitary Fibrous Tumors 2 Sarcoma, Alveolar Soft Part 2 Neuroblastoma 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Melanoma Neoplasms 1 Lung Neoplasms 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1 Liposarcoma 1

Interventions

pembrolizumab 1 Temozolomide 1 Paclitaxel 1 Dacarbazine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07310784 2026-03-03

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡